title: [Innovations in the treatment of osteoporosis].
authors: Bereich Endokrinologie/Diabetes/Knochenerkrankungen, Medizinische Klinik und Poliklinik III, Technische Universität Dresden.
authors: E
authors: E
authors: Tsourdi
authors: L C
authors: LC
authors: Hofbauer
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors; D056657:Cathepsin K / Q000037:antagonists & inhibitors; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D005819:Genetic Markers; D005858:Germany; D006801:Humans; D055118:Medication Adherence; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000517:prevention & control; D053245:RANK Ligand / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D004164:Diphosphonates; D015507:Drugs, Investigational; D005819:Genetic Markers; D053245:RANK Ligand; C422903:SOST protein, human; C557282:romosozumab; D000069448:Denosumab; D056657:Cathepsin K; C527128:odanacatib